Combined enzyme replacement therapy and hematopoietic stem cell transplantation in mucopolysacharidosis type VI

17Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Mucopolysaccharidosis type VI, Maroteaux–Lamy syndrome is a lysosomal storage disorder with progressive, multisystem involvement caused by deficiency of the lysosomal enzyme N-acetylgalactosamine-4-sulfatase leading to accumulation of the glycosaminoglycan, keratan sulfate. Enzyme replacement therapy (ERT) has been shown to clinically benefit affected individuals. A combined treatment regime of ERT and hemopoietic stem cell transplantation (HSCT) has led to reduced morbidity and mortality in patients with MPS I. We have demonstrated that a treatment regime of ERT combined with HSCT in a 3-year-old girl with MPS VI provided similar benefit. This treatment regimen should be considered in the management of selected patients with MPS VI. Neither HSCT nor ERT can correct or completely prevent progression of the musculoskeletal complications. Long-term follow-up and regular assessments for these complications is necessary.

Cite

CITATION STYLE

APA

Sillence, D., Waters, K., Donaldson, S., Shaw, P. J., & Ellaway, C. (2012). Combined enzyme replacement therapy and hematopoietic stem cell transplantation in mucopolysacharidosis type VI. In JIMD Reports (Vol. 2, pp. 103–106). Springer. https://doi.org/10.1007/8904_2011_56

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free